Mevion Medical Systems has announces an agreement with Chiyoda Technol for the exclusive distribution of the MEVION S250 proton therapy system in the Japanese market.
The MEVION S250 proton therapy system is a unique proton therapy platform – a single-room, gantry-mounted proton accelerator that frees hospitals and private treatment facilities from the astronomical costs, prohibitive space requirements and cumbersome workflow that to date have defined this effective treatment modality.
Chiyoda Technol president Kazuhiko Yamaguchi noted that the significantly reduced size and cost of the MEVION S250, paired with cutting-edge technology is a perfect fit for the very progressive Japanese radiation therapy market.
"We have a strong tradition of introducing state-of-the-art medical products and, with the addition of the MEVION S250 Proton Therapy System, we are fulfilling the demand of our foremost customers and we expect to significantly increase the number of proton therapy centers in the next 5 years," Yamaguchi added.
The MEVION S250 is installed at the Kling Proton Therapy Center at Barnes-Jewish Hospital at Washington University in St. Louis, benefiting pediatric patients and other cancer patients where proton therapy treatment is indicated.
Five additional MEVION S250 proton therapy systems are under installation at Robert Wood Johnson University Hospital in New Brunswick; Stephenson Cancer Center at the University of Oklahoma in Oklahoma City; First Coast Oncology in Jacksonville; University of Florida Health Cancer Center at Orlando Health; and University Hospitals Seidman Cancer Center in Cleveland.